Predict your next investment

Fabric Genomics company logo
Corporation
INTERNET | Internet Software & Services / Healthcare
fabricgenomics.com

See what CB Insights has to offer

Executives

4

Board of Directors

3

Fabric Genomics Board of Directors

3 Board of directors

Fabric Genomics has 3 board of directors, including John Stuelpnagel.

Name

Firm

Work History

Other Seats

John Stuelpnagel

Dr. Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function. John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008. Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

Fabric Genomics

Matt Posard

Mr. Posard brings over 30 years experience of general management and commercialization experience in the biotechnology industry. Matt’s expertise is introducing novel and transformational products to medical and research markets while scaling organizations efficiently. Matt has held executive title responsibilities with several highly successful growth companies including Illumina, Biosite and Gen-Probe. From 2006 to 2015, Matt held executive positions at Illumina as its VP of Marketing, VP Global Sales and then as Senior VP, General Manager of its Translational and Consumer Genomics and New and Emerging Markets business units. Matt currently serves on multiple boards including Halozyme Therapeutics (NASDAQ: HALO), Dermtech, Talis Biomedical, Ignite Bio, and Fabric Genomics. Matt holds a Bachelors degree in Management Science from UC San Diego.

Fabric Genomics

Michael Aicher

Fabric Genomics

Name

John Stuelpnagel

Matt Posard

Michael Aicher

Firm

Work History

Dr. Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function. John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008. Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

Mr. Posard brings over 30 years experience of general management and commercialization experience in the biotechnology industry. Matt’s expertise is introducing novel and transformational products to medical and research markets while scaling organizations efficiently. Matt has held executive title responsibilities with several highly successful growth companies including Illumina, Biosite and Gen-Probe. From 2006 to 2015, Matt held executive positions at Illumina as its VP of Marketing, VP Global Sales and then as Senior VP, General Manager of its Translational and Consumer Genomics and New and Emerging Markets business units. Matt currently serves on multiple boards including Halozyme Therapeutics (NASDAQ: HALO), Dermtech, Talis Biomedical, Ignite Bio, and Fabric Genomics. Matt holds a Bachelors degree in Management Science from UC San Diego.

Other Seats

Fabric Genomics

Fabric Genomics

Fabric Genomics

Fabric Genomics Management Team

4 Team Members

Fabric Genomics has 4 executives. Fabric Genomics's former Chief Executive Officer is Matt Tindall.

Name

Work History

Title

Status

Matt Tindall

Wheatsheaf Investments, IMS Health, Blaffin, and Digitas Health

Chief Executive Officer

Former

Ivy Chan

Chief Financial Officer

Former

Jeremy Bruestle

Chief Architect

Former

Francisco M De La Vega D Sc

Senior Vice President

Former

Name

Matt Tindall

Ivy Chan

Jeremy Bruestle

Francisco M De La Vega D Sc

Work History

Wheatsheaf Investments, IMS Health, Blaffin, and Digitas Health

Title

Chief Executive Officer

Chief Financial Officer

Chief Architect

Senior Vice President

Status

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.